Ikaros与儿童急性淋巴细胞白血病

摘要/Abstract

摘要：Ikaros是造血细胞分化和免疫系统发育的重要调节因子，并且作为肿瘤抑制因子，Ikaros异常会阻滞T、B细胞的发育或导致肿瘤形成。在白血病患者中，Ikaros发生突变导致患者治疗反应下降及长期生存率降低。Ikaros在白血病发生和预后中的机制研究已成为人们关注的热点。

易丽君；段君凯；李红. Ikaros与儿童急性淋巴细胞白血病[J]. 国际肿瘤学杂志, 2015, 42(4): 316-318.

YI Li-Jun-；Duan-Jun-Kai-；Li-Hong. Ikaros and childhood acute lymphoblastic leukemia[J]. Journal of International Oncology, 2015, 42(4): 316-318.

［1］ Cobb BS, MoralesAlcelay S, Kleiger G, et al. Targeting of Ikaros to pericentromeric heterochromatin by direct DNA binding［J］. Genes Dev, 2000, 14(17): 21462160. ［2］ Ishimaru F. Expression of Ikaros isoforms in acute lymphoblastic leukemia cell lines［J］. J Clin Oncol, 2000, 18(6): 13951397. ［3］ Dovat S, Payne KJ. Tumor suppression in T cell leukemia—the role of Ikaros［J］. Leuk Res, 2010, 34(4): 416417. ［4］ Meyer C, Zur Stadt U, Escherich G, et al. Refinement of IKZF1 recombination hotspots in pediatric BCPALL patients［J］. Am J Blood Res, 2013, 3(2): 165173. ［5］ Sellars M, Kastner P, Chan S. Ikaros in B cell development and function［J］. World J Biol Chem, 2011, 2(6): 132139. ［6］ Ma S, Pathak S, Mandal M, et al. Ikaros and aiolos inhibit preBcell proliferation by directly suppressing cMyc expression［J］. Mol Cell Biol, 2010, 30(17): 41494158. ［7］ Lo K, Landau NR, Smale ST. LyF1, a transcriptional regulator that interacts with a novel class of promoters for lymphocytespecific genes［J］. Mol Cell Biol, 1991, 11(10): 52295243. ［8］ Georgopoulos K, Moore DD, Derfler B. Ikaros, an early lymphoidspecific transcription factor and a putative mediator for T cell commitment［J］. Science, 1992, 258(5083): 808812. ［9］ Lopez RA, Schoetz S, DeAngelis K, et al. Multiple hematopoietic defects and delayed globin switching in Ikaros null mice［J］. Proc Natl Acad Sci USA, 2002, 99(2): 602607. ［10］ Ng SY, Yoshida T, Zhang J, et al. Genomewide lineagespecific transcriptional networks underscore Ikarosdependent lymphoid priming in hematopoietic stem cells［J］. Immunity, 2009, 30(4): 493507. ［11］ Kim J, Sif S, Jones B, et al. Ikaros DNA binding proteins direct formation of chromatin remodeling complexes in lymphocytes［J］. Immunity, 1999, 10(3): 345355. ［12］ Sridharan R, Smale ST. Predominant interaction of both Ikaros and Helios with the NuRD complex in immature thymocytes［J］. J Biol Chem, 2007, 282(41): 3022730238. ［13］ Kathrein KL, Chari S, Winandy S. Ikaros directly represses the notch target gene Hes1 in a leukemia T cell line: implications for CD4 regulation［J］. J Biol Chem, 2008, 283(16): 1047610484. ［14］ Papaemmanuil E, Hosking FJ, Vijayakrishnan J, et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia［J］. Nat Genet, 2009, 41(9): 10061010. ［15］ Heerema NA, Nachman JB, Sather HN, et al. Deletion of 7p or monosomy 7 in pediatric acute lymphoblastic leukemia is an adverse prognostic factor: a report from the Children′s Cancer Group［J］. Leukemia, 2004, 18(5): 939947. ［16］ Dupuis A, Gaub MP, Legrain M, et al. Biclonal and biallelic deletions occur in 20% of BALL cases with IKZF1 mutations［J］. Leukemia, 2013, 27(2): 503507. ［17］ Yoshida T, Georgopoulos K. Ikaros fingers on lymphocyte differentiation［J］. Int J Hematol, 2014, 100(3): 220229. ［18］ Virely C, Moulin S, Cobaleda C, et al. Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCRABL in a transgenic model of acute lymphoblastic leukemia［J］. Leukemia, 2010, 24(6): 12001204. ［19］ Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of children acute lymphoblastic leukaemia with poor treatment outcom: a genomewide classification study［J］. Lancet Oncol, 2009, 10(2): 125134. ［20］ Mullighan CG, Miller CB, Radtke I, et al. BCRABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros［J］. Nature, 2008, 453(7191): 110114. ［21］ Medeiros BC. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia［J］. N Engl J Med, 2009, 360(17): 470480. ［22］ Krentz S, Hof J, Mendioroz A, et al. Prognostic value of genetic alterations in children with first bone marrow relapse of childhood Bcell precursor acute lymphoblastic leukemia［J］. Leukemia, 2013, 27(2): 295304. ［23］ van der Veer A, Zaliova M, Mottadelli F, et al. IKZF1 status as a prognostic feature in BCRABL1positive childhood ALL［J］. Blood, 2014, 123(11): 16911698.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维.Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华.炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[4]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[5]	刘萍萍, 何学芳, 张翼, 杨旭, 张珊珊, 季一飞.原发性脑胶质瘤患者术后复发危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(4): 193-197.
[6]	万芳, 杨钢, 李睿, 万启晶.食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[7]	姚益新, 沈煜霖.血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[8]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好.基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[9]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹.胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[10]	彭琴, 蔡玉婷, 王伟.KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.
[11]	滕远, 李莉娟, 张连生.MCL-1及其抑制剂在血液恶性肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 119-122.
[12]	陈波光, 王苏贵, 张永杰.血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[13]	金旭东, 陈忠坚, 毛伟敏.MTAP基因在恶性间皮瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 99-104.
[14]	黄镇, 陈永顺.循环肿瘤DNA在肝细胞癌诊疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(1): 59-64.
[15]	王潇, 李盈, 罗玉杰, 晋舒.基于列线图模型探讨血清学指标对鼻咽癌预后的判断价值[J]. 国际肿瘤学杂志, 2023, 50(8): 463-469.

Ikaros与儿童急性淋巴细胞白血病

Ikaros and childhood acute lymphoblastic leukemia

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章15

编辑推荐

Metrics

本文评价